Biogen Inc. (BMV:BIIB)

Paycor HCM Statistics

Total Valuation

Biogen has a market cap or net worth of MXN 350.45 billion. The enterprise value is 422.08 billion.

Market Cap	350.45B
Enterprise Value	422.08B

Important Dates

The last earnings date was Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.53M
Shares Outstanding	n/a
Shares Change (YoY)	+0.31%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.22M

Valuation Ratios

The trailing PE ratio is 12.14 and the forward PE ratio is 8.39.

PE Ratio	12.14
Forward PE	8.39
PS Ratio	1.86
PB Ratio	1.05
P/TBV Ratio	11.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.77, with an EV/FCF ratio of 11.31.

EV / Earnings	14.62
EV / Sales	2.26
EV / EBITDA	6.77
EV / EBIT	9.12
EV / FCF	11.31

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.37.

Current Ratio	2.50
Quick Ratio	1.52
Debt / Equity	0.37
Debt / EBITDA	1.97
Debt / FCF	3.33
Interest Coverage	9.82

Financial Efficiency

Return on equity (ROE) is 9.13% and return on invested capital (ROIC) is 6.62%.

Return on Equity (ROE)	9.13%
Return on Assets (ROA)	5.62%
Return on Invested Capital (ROIC)	6.62%
Return on Capital Employed (ROCE)	9.85%
Revenue Per Employee	24.79M
Profits Per Employee	3.80M
Employee Count	7,605
Asset Turnover	0.36
Inventory Turnover	1.02

Taxes

In the past 12 months, Biogen has paid 5.04 billion in taxes.

Income Tax	5.04B
Effective Tax Rate	14.86%

Stock Price Statistics

The stock price has decreased by -40.02% in the last 52 weeks. The beta is 0.13, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.13
52-Week Price Change	-40.02%
50-Day Moving Average	3,163.31
200-Day Moving Average	4,310.18
Relative Strength Index (RSI)	33.02
Average Volume (20 Days)	93

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.62

Income Statement

In the last 12 months, Biogen had revenue of MXN 188.53 billion and earned 28.86 billion in profits. Earnings per share was 197.14.

Revenue	188.53B
Gross Profit	142.50B
Operating Income	46.73B
Pretax Income	33.90B
Net Income	28.86B
EBITDA	60.77B
EBIT	46.73B
Earnings Per Share (EPS)	197.14

Balance Sheet

The company has 52.03 billion in cash and 124.36 billion in debt, giving a net cash position of -72.34 billion.

Cash & Cash Equivalents	52.03B
Total Debt	124.36B
Net Cash	-72.34B
Net Cash Per Share	n/a
Equity (Book Value)	332.55B
Book Value Per Share	2,268.39
Working Capital	90.22B

Cash Flow

In the last 12 months, operating cash flow was 39.92 billion and capital expenditures -2.60 billion, giving a free cash flow of 37.31 billion.

Operating Cash Flow	39.92B
Capital Expenditures	-2.60B
Free Cash Flow	37.31B
FCF Per Share	n/a

Margins

Gross margin is 75.58%, with operating and profit margins of 24.79% and 15.31%.

Gross Margin	75.58%
Operating Margin	24.79%
Pretax Margin	17.98%
Profit Margin	15.31%
EBITDA Margin	32.23%
EBIT Margin	24.79%
FCF Margin	19.79%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.31%
Shareholder Yield	n/a
Earnings Yield	8.24%
FCF Yield	10.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3.16 and a Piotroski F-Score of 6.

Altman Z-Score	3.16
Piotroski F-Score	6